Independent analysis of commercial transformation across life sciences in Europe
Life Sciences Commercial Transformation in Europe — Strategy, Market Signals, and What Comes Next
Commercialization, regulation, AI, and operating-model shifts shaping pharma, MedTech, and digital health in Europe – from an operator’s perspective.
Weekly Life Sciences Signal
Weekly analysis of funding, regulation, AI, commercial moves, and execution signals shaping life sciences in Europe.
Europe Life Sciences Weekly Signal #39 Acquiring Is Not Operating
Week of 25–31 May 2026 Life sciences organisations have never had more ways to acquire capability. They can buy pipelines, license products, enter new geographies through partnerships, deploy increasingly sophisticated AI platforms, or secure access to new markets through regulatory approvals. Capital remains available for the right assets, technology has become easier to access, and…
Europe Life Sciences Weekly Signal #38: Where Launches Are Really Decided
Week of 18–24 May 2026 This week looked fragmented at first glance: a US approval for a hypertension medicine, Veeva’s commercial software summit, CHMP opinions on oral Wegovy and biomarker-led oncology, EUDAMED’s approaching deadline, and EMA’s breakthrough device pilot closing its first application window. They are not fragmented. The common thread is upstream commercial design….
Europe Life Sciences Weekly Signal #37: When the Operating Layer Becomes the Strategy
Week of 11–17 May 2026 The procedural week was supposed to be quiet. It was anything but. Bristol Myers Squibb committed up to $15.2 billion to Hengrui across 13 early-stage programmes. Roche bought deeper into AI diagnostics. Bayer’s Q1 numbers showed the commercial cost of patent-cliff transition in plain sight. NICE recommended AstraZeneca’s Imfinzi for…
Get the Weekly Life Sciences Signal
Funding, regulation, AI, and strategic moves shaping life sciences in Europe in one sharp weekly read.
Strategic Perspectives on European Life Sciences
Life Sciences Market Intelligence
Funding, valuations, and strategic moves.
Commercialization & Go-to-Market
AI & Digital Health
About
Piotr Wrzosinski is a life sciences commercial transformation leader with 20+ years of experience across pharma, MedTech, and consulting.
He writes about commercialization, operating models, AI, and market shifts in Europe with a practical focus on what makes transformation work at scale.